


2022 ANNUAL REPORT



July 1, 2021 - June 30, 2022

Board of Directors

EXECUTIVE COMMITTEE



Jeanine D'Armiento, MD, PhD Chair New York



Elizabeth Johnson Vice Chair Massachusetts



Fred C. Walsh 2nd Vice Chair Massachusetts



Jennifer Jopp Secretary Minnesota



Jon Hagstrom Treasurer New York



Martin R. Zamora, MD Physician-Director Colorado

BOARD MEMBERS



Faron Schonfeld Pennsylvania



Connecticut



Peggy Iverson



Ann Knebel, PhD, RN Maryland



Noel G. McElvaney, MD, BCh, BAO, FRCPI, FRCPC Ireland



James K. Stoller, MD Ohio

Our Mission



The Alpha-1 Foundation is committed to finding a cure for Alpha-1 Antitrypsin Deficiency (Alpha-1) and to improving the lives of people affected by Alpha-1 worldwide. Our initiatives in four main areas- Research, Education/Outreach, Awareness/Fundraising, and Public Policy/Advocacy are paving the way for important discoveries, new therapies, and increased awareness and understanding of this rare genetic condition.

Our accomplishments and accreditations reflect our unparalleled commitment to medical research at its finest: we have invested over \$91 million to support Alpha-1 research and programs at 123 institutions in North America, Europe, South America, the Middle East, and Australia. These innovative, impactful projects have built a solid infrastructure for promoting ongoing research and the development of new therapies. We have also fostered collaborations with investigators throughout the United States and Europe, working closely with the pharmaceutical industry, the National Institutes of Health (NIH), the U.S. Food and Drug Administration (FDA), and Alpha-1 patients and families.

There are more advancements on the horizon than ever before and our commitment to fund vital research needed to make breakthroughs in Alpha-1 is greater than ever. The Alpha-1 Research Registry is growing with enthusiastic Alphas who are ready to advance the Foundation's research goals.

During this fiscal year, we welcomed a new President and Chief Executive Officer, Scott Santarella. Scott joined the Foundation in September 2021, with over 25 years of experience as a senior executive. Scott's vision for the Alpha-1 Foundation included the continuation of achievement through forward momentum, the optimism of forward-thinking through innovation, and the advancement of impact through forward progress.

"Now is the time to accelerate our efforts across the spectrum and maximize our resources to expedite progress toward our ultimate goal –a cure," said Santarella. "It is here that patients play the most vital role. The key to solving the Alpha-1 puzzle will be found in the patient."

We utilized innovative and creative ways to connect the community through this part of the pandemic. Hybrid event options transformed the way we served the community in all of our programs. A COVID event grid was created to provide a framework on how to resume in-person events while keeping the safety of Alphas a top priority. We were able to host the annual Alpha-1 National Conference in a hybrid fashion in 3 cities across the United States, assuming a unique blend of online presentations using our robust virtual environment with interactive features. This was just the first step in our path to a "new normal."

Alpha-1 Outreach & Education

Our website, www.alphal.org, is a clearinghouse for information on Alpha-1 providing educational resources, highlighting news and upcoming events, and creating opportunities for virtual connection within the global Alpha-1 community. We maintain content targeted toward several different audiences, including newly diagnosed Alphas, family members and caregivers, healthcare providers, researchers, and industry partners. The website received over 484,000 visits from over 234,000 unique visitors in FY 2022. The Alpha-1 Foundation's website is most often the first contact that newly diagnosed Alphas and their family members have with the Foundation and in many cases, their first source of information about Alpha-1 Antitrypsin Deficiency.

We connect with the Alpha-1 community across multiple social media platforms. In addition to promoting new Foundation initiatives, community education events, and fundraising campaigns, our presence on Facebook, Instagram, and Twitter has directly increased traffic to our website, where users can access the information they need.

The monthly Community Currents electronic newsletter keeps the Alpha-1 community and volunteer leadership updated on all Alpha-1-related news, upcoming events, research, programs, fundraising activities, and the Alpha-1 Research Registry.

The Alpha-1-to-One Magazine is a valued resource produced three times a year for the Alpha-1 community offering practical advice, personal experiences, and pertinent news for people touched by Alpha-1. In FY 2022, we distributed 30,000 printed copies of each issue, including bundles to Clinical Resource Centers (CRCs) and healthcare providers; each issue is also posted to a digital publishing platform on our website, where it is accessed by nearly 2,000 more visitors a year. In the Fall issue of the magazine "All In For Alpha-1" spotlighted the 2021 Virtual Alpha-1 National Conference. In the Winter issue "Riding for a Reason" focused on the 25th anniversary of Escape to the Cape Bike Trek. The Spring issue's theme "Forward Momentum" welcomed Scott Santarella as the new President and CEO of the Alpha-1 Foundation.



Alpha-1 Advocates


Our advocates are a voice to improve outcomes for Alpha-1 patients. Together, we are fighting to improve the fact that Alpha-1 is under-recognized, under-diagnosed, and unknown to most people by ensuring our community's priorities are factored into public policy and legislation. Our advocacy program targets policymakers, regulatory agencies, the public, and the media with campaigns to promote research and raise awareness of the challenges faced by Alpha-1 patients and care providers. Our FY 2022 policy priorities included access to care, medical research, therapeutic development, screening and detection, federal and state funding, blood product safety, and education and awareness.

We worked with Congress to find a solution to the patient access problem facing Medicare beneficiaries who are not able to obtain a home infusion. In March 2022, the John W. Walsh Home Infusion Act introduced a permanent benefit for Alphas to receive augmentation therapy in the home setting through Medicare Part B. This process is ongoing, and we continue to work diligently with advocates and legislators to meet the needs of the Alpha-1 community.

We work strategically with federal agencies, memberships, and coalitions—focusing on the issues that matter most to Alphas—to inform legislators of the burdens of the patient community and to advance our public policy agenda for the benefit of the Alpha-1 community.

Additionally, working closely with the U.S. Food and Drug Administration (FDA), Critical Path Institute (C-Path), and National Institutes of Health (NIH).

- November 10, 2021, Fall Virtual Lobby Day
- Fall Advocacy Training Series
- 2022 Rare Disease Day



Alpha-1 Education Days



FY 2022 Alpha-1 Education Days:

October 2, 2021

November 6, 2021

February 12, 2022

March 26, 2022

April 30, 2022




The Alpha-1 National Education Series is comprised of regional Alpha-1 Education Days for Alphas, their families, and caregivers. These one-day educational programs provide access to current medical information, timely topics affecting Alphas, resources from leading Alpha-1 experts, and opportunities to connect with the Alpha-1 community.

In 2022, we continued our use of a virtual event platform, enabling those who were unable to attend an Alpha-1 Education Day in person to participate and connect with the Alpha-1 community. Extending our education series into the virtual space has also created community-building and engagement opportunities through more direct access to social media, polls, and surveys.

More than 2,300 people registered for the FY 2022 Alpha-1 Education Days.

Alpha-1 National Conference

As the largest gathering of the Alpha-1 community, the National Conference provides important opportunities for networking, education, advocacy, and industry publicity. Over the course of four days, attendees had access to scientific presentations, meet-and-greet and Q&A sessions with Alpha-1 experts, and other events hosted by sponsors.



After two years of completely virtual programming, we were proud to announce that the first-ever Hybrid Alpha-1 National Conference was held on June 2022. The format of the Hybrid Alpha-1 National Conference was meticulously crafted in a way that sought to combine the best aspects of the traditional in-person format while also continuing to provide the accessibility and flexibility offered by a virtual format. Three sites were selected to represent major regions in the United States: New York City, Miami, and Oregon. Each site is also home to one of the Foundation's Clinical Resource Centers (CRCs), specialized locations that give patients access to doctors who are familiar with Alpha-1. The four-day agenda was packed with engagement and interaction, including three Platinum Sponsor live events, three phenomenal keynote speakers, eighteen open forum question and answer breakout sessions, three live panel sessions, and ondemand education sessions throughout the conference. Presentations from the conference were available to view on-demand on the Foundation's Vimeo channel.

Stats: 1,195 registered to attend

667 attended from 47 states and 10 countries

510 patients and family members

53 medical professionals

23% of first-time attendees



Meetings and Conferences

Scientific meetings and conferences organized by the Alpha-1 Foundation generate awareness of Alpha-1, identify new areas of research interest, and establish the Foundation's credibility within the rare disease community as a resource for serious research, education, and advocacy.



The 23rd Gordon L. Snider Critical Issues Workshop entitled "Liver Biomarkers and the Path to Alpha-1 Liver" was held on November 19, 2021. The overall goal of the workshop was to bring together researchers, clinicians, and industry representatives to focus on identifying biomarkers to support the path to drug approval in liver disease. Cochaired by Virginia Clark, MD, MS from the University of Florida and Pavel Strnad, MD from University Hospital/Aachen.

"Outstanding speakers and the co-chairs brought into sharp focus both challenges and pathways to drug approval in a new era of drugs to treat Alpha-1 Antitrypsin Deficiency related liver disease," stated Dr. Mark Brantly, Alpha-1 Foundation Scientific Director.

We reach thousands of physicians, academic researchers, and industry partners each year through our exhibitions at major national and international medical conferences, where we share insights into new technologies, research findings, and priority research areas.

The CRC Forum took place on June 30, 2022, and was an opportunity to engage Alpha-1 physician specialists and leaders in the field of Alpha-1 research and the patient community to learn about new Foundation programs, research initiatives, and updates from industry sponsors.

Alpha-1 Awareness

Annual campaigns help facilitate community support and improved approaches to care.

#AlphalAwareness- November is Alpha-1 Awareness Month: 30 days of awareness-focused initiatives, through which the Alpha-1 community shares stories and resources while raising funds to support the search for a cure. A dedicated webpage, online training, digital resources, media outreach, community events, and a social media calendar are available throughout November specifically for awareness. The 2021 Alpha-1 Virtual Walks allowed anyone who wanted to make a difference in the Alpha-1 community to contribute in their own style, time, and pace. Over 700 participants tracked miles on STRAVA and raised over \$72,000 for Alpha-1 in just one month.



#RareDiseaseDay - During the month of February, we collaborated with the National Organization for Rare Disorders (NORD) to spread awareness of Alpha-1 on Rare Disease Day. The goal was to get patients interested and involved in rare disease research.

Family Testing

Alpha-1 Coded Testing (ACT) Study has enrolled over 47,000 individuals since collecting data on the impact of at-home confidential genetic testing. The ACT study is a confidential testing program aimed at those who are at risk of Alpha-1, it provides an opportunity for individuals and their family members to be tested for Alpha-1 in the privacy of their homes, without the concern for health and life insurance issues associated with a diagnosed pre-existing condition.



The study screened 1,897 people in FY 2022 and 52% of those tested were identified as carriers of Alpha-1 and 5% were diagnosed as ZZ Alphas.

Community Fundraisers

Our Building Friends for a Cure (BFC) community fundraisers are designed to increase awareness and promote research. Support from the Alpha-1 community is a critical component of our goal to raise awareness of the disease and treatment options. Through the BFC program, we steward relationships with donors to boost awareness of Alpha-1 and get the community involved in working towards a cure.





Building Friends for a Cure consisted of a series of community fundraising events this year in support of Alpha-1 research, including:

- · Riding for a Reason
- Escape to the Cape
- Alpha-1 Virtual Walks
- Celtic Connection
- Walks, Run, and Marathons
- · Alpha Hours
- Climbs and Hikes
- Video Game Streaming Marathons
- Golf Tournaments

Research Grant Awards

The Alpha-1 Foundation directed more than \$2 million in peer-reviewed research grants in FY 2022. These grants support innovative research spanning the spectrum of scientific discovery. The Foundation prides itself on being the #1 funders in Alpha-1 research having invested over \$90 million at 128 institutions in 14 countries worldwide. Research funded by the Alpha-1 Foundation has improved our understanding of the mechanisms underlying the clinical manifestations of Alpha-1 and identified novel drug targets likely to lead to new therapeutic solutions.

The Foundation is proud to announce its in-cycle grant awardees for 2022, with 11 grant recipients receiving over \$2 million for their projects. Of this year's grant recipients' fields of study, 45.5 % were lung focused, 36.4 % were liver-focused and 18.2 % were focused in both areas. The research was focused 72.7% on basic research and 27.3 on translational research, keeping a well-rounded portfolio.



Brian Hobb, MD Brigham and Women's Hospital

"Inflammatory Protein Biomarkers of Reduced Lung Function in AATD"

"Mechanisms of Hepatic Heterogeneity and ATF6 Mediated Metabolic Dysfunction in AATD"



Joseph Kaserman, MD Boston University



Jarrett Morrow, PhD Brigham and Women's Hospital

"Blood and Lung Microbiome in Alpha-1 Antitrypsin Deficiency"

"Mitochondrial Dysfunction in Alpha-1 Antitrypsin Deficiency Associated Liver Disease"



Pasquale
Piccolo, PhD
Telethon Institute of
Genetics and Medicine

Research Grant Awards



Francesco
Annunziata, PhD
Telethon Institute
of Genetics and
Medicine (TIGEM)
Naples, Italy

"Identification and Modulation of Local and Systemic Environmental Factors in AATD"

"Severity and progression of airway dropout in AAT knockout transgenic ferret model of COPD"



Shah Hussain, PhD University of Alabama at Birmingham



George Sophocleous, PhD University College London

"Structural and biophysical dissection of the alpha-1 antitrypsin polymerization pathway"

"Modulating the Co-Translational Misfolding and Polymerization of Antitrypsin"



Lisa Carita, PhD, BSc University College London



Tomas
Carroll, PhD
Royal College of
Surgeons in Ireland

"A Family Affair- Clarifying the Risk of Lung Disease in ZZ AATD"

"Longitudinal Evaluation of Lung Disease Progression in PiMZ Patients"



Monica
Goldklang, MD
Columbia
University Irving
Medical Center



Valerie Gouon-Evans, PhD Boston Medical Center

"Engineered and Edited Patient-Derived iPSC for AATD-Associated Liver Disease Cell Therapy"

Statement of Financial Position

Current Assets	2022	2021
Cash and cash equivalents	\$12,377,362	\$8,614,083
Investment securities	\$16,836,191	\$18,369,431
Accounts receivable	\$675,117	\$982,721
Other current assets	\$167,500	\$21,728
Total Current Assets	\$30,056,170	\$27,987,963
Investment securities- non- current	\$5,039,394	\$6,432,525
Investment in TAP	\$363,069	\$136,115
Property and equipment, net	\$12,983	\$21,749
Other assets	\$25,000	\$25,134
Total assets	\$35,496,616	\$34,603,486
Current Liabilities	2022	2021
Current Liabilities Accounts payable and accrued expenses	\$1,908,720	\$1,951,672
Accounts payable and accrued		
Accounts payable and accrued expenses	\$1,908,720	\$1,951,672
Accounts payable and accrued expenses Refundable advances	\$1,908,720 \$505,000	\$1,951,672 \$130,000
Accounts payable and accrued expenses Refundable advances Deferred revenue	\$1,908,720 \$505,000 \$210,000	\$1,951,672 \$130,000 \$286,000
Accounts payable and accrued expenses Refundable advances Deferred revenue Total current liabilities	\$1,908,720 \$505,000 \$210,000 \$2,623,720	\$1,951,672 \$130,000 \$286,000 \$2,367,672
Accounts payable and accrued expenses Refundable advances Deferred revenue Total current liabilities Net Assets	\$1,908,720 \$505,000 \$210,000 \$2,623,720 2022	\$1,951,672 \$130,000 \$286,000 \$2,367,672 2021
Accounts payable and accrued expenses Refundable advances Deferred revenue Total current liabilities Net Assets Without donor restrictions	\$1,908,720 \$505,000 \$210,000 \$2,623,720 2022 \$28,669,884	\$1,951,672 \$130,000 \$286,000 \$2,367,672 2021 \$29,114,292

Statement of Activities & Changes in Net Assets

Changes in net assets without donor restrictions	2022	2021
Contributions, bequests and grant revenues	\$6,211,034	\$5,385,961
Donated securities	-	\$10,230
Fundraising revenues	\$49,150	\$52,684
Net realized and unrealized investment (losses)/gains	(\$3,267,543)	\$4,778,951
Interest and dividends	\$465,634	\$460,729
In-kind rental income	\$210,000	\$200,000
Net assets released from restriction	\$2,447,606	\$1,816,820
Other Income	\$374,788	\$248,788
Total support/revenue without donor restrictions	\$6,490,669	\$12,954,163
Expenses	2022	2021
Research and Clinical Studies	\$3,450,654	\$3,713,401
Patient Education	\$1,197,628	\$1,075,527
Patient Advocacy	\$429,678	\$288,876
Total program services	\$5,077,960	\$5,077,804
Administrative and general	\$555,657	\$492,150
Fund raising	\$628,414	\$550,275
Total supporting services	\$1,184,071	\$1,042,425
Total expenses	\$6,262,031	\$6,120,229
Change attributed to income (loss) from TAP	\$226,954	\$1,427
Increase in net assets without donor restrictions	\$455,592	\$6,835,361
Changes in net assets without donor restrictions	2022	2021
Contributions, bequests and grant revenues	\$2,629,096	\$2,343,702
Net assets released from restriction	(\$2,447,606)	(\$1,816,820)
Increase in net assets with donor rescrictions	\$181,490	\$526,882
Increase in net assets	\$637,082	\$7,362,243
Net assets, beginning of year	\$32,235,814	\$24,873,571
Net assets, end of year	\$32,872,896	\$32,235,814

The Alpha-1 Foundation is committed to finding a cure for Alpha-1 Antitrypsin Deficiency (Alpha-1) and improving the lives of people affected by Alpha-1 worldwide. The Alpha-1 Foundation has invested more than \$91 million to support Alpha-1 research and programs at more than 123 institutions in North America, Europe, the Middle East, and Australia.

The Alpha-1 Research Registry is a confidential database of people with Alpha-1 (Alphas) and Alpha-1 carriers. It is a resource for investigators seeking Alphas to participate in clinical trials, surveys, and other scientific and medical activities. For more information, email alphalregistry@alphal.org or call toll-free 1-877-228-7321 ext. 252. https://www.alphal.org/alphas-friends-family/resources/participate-in-research/.

Alpha-1 Coded Testing provides free, confidential testing administered through a research study that evaluates the perceived risks and benefits of genetic testing. For more information, email alphallab@alphaone.ufl.edu or call toll-free 1-855-476-1227 https://www.alphal.org/healthcare-providers/testing-and-treatment/alpha-1-coded-testing-study/.

The Support Network is comprised of over 80 support groups nationwide that provide guidance and education to Alphas and family members, create awareness in local communities, and advocate for national and state issues that affect Alphas. Four Virtual Support Groups provide a forum for topics such as Alpha-1 Kids, Pre & Post Transplant issues, Caregivers, and Timely Topics. To find a support group near you, visit alf.org/support-groups.

The Patient Information Line 1-800-245-6809 is available free of charge to anyone affected by Alpha-1 and provides support and answers to topics such as Alpha-1 testing, emotional impact, and physician and support group referrals.

The Genetic Counseling Program 1-855-476-1227, based at the University of Florida, is a free and confidential service that provides direct contact with a genetic counseling service to provide information on the risks and benefits of testing for Alpha-1, interpreting test results, understanding the genetics of Alpha-1, and other issues associated with having a genetic illness. https://www.alphal.org/alphas-friends-family/support/genetic-counseling/

The Peer Guide Program 1-877-346-3212 connects newly diagnosed Alphas with other Alphas who have a similar set of circumstances to provide emotional support, discuss resources available, and assist in making choices about health.

The Oxygen Fund provides oxygen equipment for Alphas in financial need to travel to physicians, hospitals, Alpha-1 educational events, and other activities. For more information contact Joy Collins at jcollins@alpha1.org or call 1-877-228-7321 ext. 251. https://www.alpha1.org/alphas-friends-family/resources/oxygen-resources/

Patient Education Programs include an annual National Education Conference which brings together over 600 Alphas, caregivers, industry representatives, clinicians, allied healthcare workers, and scientists to discuss a wide range of Alpha-1-related topics. For more information, visit alf.org/alphalconference. Additionally, a series of Alpha-1 Education Days are held each year in various cities throughout the U.S. to bring patient education to a regional audience. For more information, visit alf.org/educationdays. Recordings of these events are available via E-Education at alf.org/education-videos.

Building Friends for a Cure is a program designed to nurture ongoing friendships in the Alpha-1 community. The goal is to increase awareness and raise funds for research and related programs which will ultimately lead to a cure for Alpha-1. By becoming involved in fundraising efforts, such as virtual events, letter-writing campaigns, and other social and sporting events, you are making a difference. Visit alf.org/building-friends, contact amcbride@alphal.org, or call 1-877-228-7321 ext. 233 for more information.

The Alpha-1 Kids Program is geared to the special needs and concerns of parents of children with Alpha-1. A committee of volunteer parents helps direct the program, which consists of a hotline, age-appropriate informational books, a virtual support group, and a parent peer guide program. For more information, visit alf.org/alphal-kids or contact Cathey Henderson at chenderson@alphal.org.

Educational resources about Alpha-1 and related topics are available for Alphas, their families, caregivers, and healthcare providers. Informational brochures such as 'What is Alpha-1?', Am I an Alpha Carrier?', 'The Liver and Alpha-1', and 'It's All In The Family: Family Testing' are available to download and order through our website, alf.org/al-publications, or by calling toll-free 1-877-228-7321 ext. 251. The Alpha-1 to One Magazine is published three times a year and includes timely articles about Alpha-1 research and Alpha life, as well as answers from Alpha-1 experts to questions from the Alpha-1 Community. Join the mailing list here at alphal.org/alphas-friends-family/resources/join-mailing-list/ to receive the magazine. Presentations from previous Alpha-1 educational events are available via E-Education at alf.org/education-videos.

The Foundation's Public Policy Program advocates for the Alpha-1 community by monitoring and influencing legislative and regulatory issues. Primary concerns include stimulating medical research, blood product safety, developing new therapies, screening, and detection, access to care and reimbursement, federal and state funding, education, awareness, and the recognition of the special needs of people with Alpha-1. For more information, contact Jeanne Kushner at jkushner@alpha1.org or call 1-877-228-7321 ext. 204 or visit alf.org/action-alert.

Grants and Awards: The Foundation's peer-reviewed grants program is intended to promote research that will lead to improved health for Alphas and ultimately, find a cure. We offer grants for both basic science and clinical research. For more information, contact Vanessa Valencia at vvalencia@alphal.org or call 1-877-228-7321 ext. 242.

The Alpha-1 Foundation DNA & Tissue Bank at the University of Florida is the central storage site for DNA and tissue samples from Alphas and other donors. The Bank is a resource for researchers investigating Alpha-1 and other conditions. Researchers should contact Vanessa Valencia at vvalencia@alpha1.org or call 1-877-228-7321 ext. 242. For other information, call toll-free 1-866-284-2708.

The Targeted Detection Program promotes worldwide awareness among medical professionals, the media, and the public, and the identification of Alphas in population groups at risk. For further information, please call 1-877-228-7321 ext. 306.

The Alpha-1 Clinical Resource Center Network is a steadily growing group of centers throughout North America that specialize in patient care and education for those with Alpha-1. Centers also offer other resources for Alphas such as support groups, transplant centers, and pulmonary rehabilitation. Alphas and their physicians are encouraged to contact their regional Clinical Resource Center for information and guidance. To find an Alpha-1 specialist near you, visit alf.org/alphaldoc. For more information, contact Vanessa Valencia at vvalencia@alphal.org or call 1-877-228-7321 ext. 242.

Scientific Meetings, Conferences, Workshops, Working Groups, and Symposia bring scientists together to focus on special topics related to Alpha-1, advance knowledge of the genetic condition, and work toward new therapies and a cure. For more information, contact Adriana De Arce at adearce@alpha1.org or call 1-877-228-7321 ext. 269.

The Alpha-1 Global Initiative works on a global, national, and local level to enhance care and support for all those affected by Alpha-1. The Foundation is committed to providing reliable resources and information worldwide. As part of the Global Alpha-1 Initiative, the Foundation is creating new tools focusing on connecting Alphas all over the world with resources – and with each other. For more information, visit alpha-1global.org, contact Randel Plant at rplant@alphal.org, or call 1-877-228-7321 ext. 306.

Access and Reimbursement: The Alpha-1 Foundation is committed to providing the tools and resources necessary to assist Alphas in making informed decisions about their healthcare plan and assistance program selection. Patients with questions or issues concerning access or reimbursement should contact Cathey Henderson at 1-800-245-6809 or chenderson@alphal.org. https://www.alphal.org/alphas-friends-family/resources/assistance-organizations/

The Clinical Trial Outreach and Education Program is an online tool used to educate Alphas about clinical trials with curated educational materials for Alpha-1. For more information, visit https://www.alphal.org/alphas-friends-family/resources/clinical-trials/or contact Alison Keaveny at akeaveny@alphal.org or call 1-877-228-7321 est. 206.

The Alpha-1 Foundation's Honor Gallery salutes the individuals, corporations, and foundations that share our commitment to finding a cure for Alpha-1 Antitrypsin Deficiency and to improving the lives of people affected by Alpha-1 worldwide. The Foundation gratefully welcomes several new members who have supported our mission for the first time through their generous contributions.

The Foundation acknowledges the continued support of the many long-time donors who have invested in our mission through contributions, events, and workplace giving. It is with sincere gratitude and appreciation that we recognize our Honor Gallery. The following is a list of donors who contributed \$500 or more between July 1, 2021 and June 30, 2022.

\$2.5 Million or More

AlphaNet, Inc.

\$1 Million - \$2,499,999

CSL Behring, L.L.C. Grifols

Takeda Pharmaceutical Company

\$500,000 - \$999,999

Estate of James L. Fermoile

\$250,000 -\$499,999

Estate of Gerald C. and Helen M. McDonough Vertex Pharmaceuticals, Inc.

\$100,000 - \$249,999

Janie Trimble

Fred M. Odom

\$25,000 - \$99,999

Accredo Health
Anonymous Donors
Midge and Greg Bertles
Estate of Robert Duncan Brown, III
Ruth and Gordon E. Cadwgan, Jr. PhD
Columbia University Medical Center
CVS Health
Meta Payments, Inc.

\$10,000 - \$24,999

Anonymous Donors
BioMarin Pharmaceutical, Inc.

Jon E. Hagstrom

Kamada, Ltd.

Judith M. Kay

Austin Locke

Mereo BioPharma Group, PLC

Wendy Becker Payton

Barbara Poresky

Mark Reschly

Elisabeth and Alan P. Sklar

The Benevity Community Impact Fund

The B.T. Rocca, Jr. Fund

The Howard V. Moore Foundation

William Gundry Broughton Charitable Private

Foundation, Inc.

\$5,000 - \$9,999

Bloomberg Philanthropies

Drs. Sarah and Aaron Cohen

Kenneth A. Irvine

William Irvine and Gillian Marcott

Peg and Peter Iverson

Holly Jackson

Gerald D. Lashway

Linden Advisors, LP

National Philanthropic Trust- Ann Linnett Pless

Novo Nordisk

Barbara Perreault

Pivot Design

Lauren and Faron Schonfeld

Lyle D. Schutte

Judith and Kenneth Simon

The Old Stones Foundation, Inc.

Carolyn P. and Matthew Vanderberg

Barbara S. Walker

Robert B. Webster

\$1,000 - \$4,999

AmazonSmile Foundation

Anonymous Donors

Arcadia Healthcare Solutions

Iris Arnowitt

Bank of America Charitable Foundation

Peter A. Basile

Ruth Berkelman, MD

Helen Beuker

Charles Bissell

Scott Blackburn

Laura Bohn

James L. Braunstein

Breathless Wines

Heidi and Jon Breyer

Chris A. Bucek

Helen E. Bueker

Anthony Callea

Erin L. Carr

John M. Carter

Estate of Donald J. Ceppi

Mary M. Chilton

Rosemary B. Chiodo

Jan and Michael Chnupa

Donna A. Clark, R.N.

Kathryn W. and Daniel C. Coffin

Jane-Ellen and Joseph Collins

Joan and Curts Cooke

Timothy J. Craig, D.O.

Creating Healthier Communities

Barbara E. and Don E. Davis, Jr.

Connie A. DeWald

James F. Donohue, M.D.

Sally D. and John H. Dorf

EchoStor Technologies- Michael McMillan

Traci and Steven Egly

Erickson Solutions Group, Inc. - Peter R.

Latessa

Evolve Biologics

Susan W. and Donald C. Ferro

Janet and Kenneth N. Findley

Louis G. Fox

Anne and Paul Friedlander

FrontStream Workplace Platform

Gain Therapeutics

Donna A. and James A. Geurink

Barbara A. Glenn

Monica P. Goldklang, MD

Google, Inc.

Goose the Market- Mollie and Chris Eley

Anne and Gary Greenwood

Michael B. Griffith

John E. Haffty

Patrick Haller

Dr. Jonathan Hamer

Mary Ann S. Hazen

HealthNet Systems Consulting, Inc.

Joanne and William Helsey

Kate and Robert Hoch

Kara L. Hodges

David R. Hoertling

Bridgette Holbrook

Patricia A. and Donald E. Janke

Melissa Johnson

Deborah H. and Richard C. Keiser

Andrew Kwatinetz

Norma I. Leising

Richard Lesher

Lynwood L. Locke

Dr. Harry Long

Catharine MacDonald

Sandra and Paul Maidment

Adam Marr

Karilynne M. Martin

John Mascavage

Medical Research Charities

Linda Mikell

Joan and Don Mill

Carolyn Sue Miller

Diane Mohr

Network for Good

Barbara K. Oman

Michael O'Mara

Cherie R. Patel

Anne L. and Michael F. Pawlowski

Laurie L. Perry

Beth E. Phillips

Ronald H. Pierce

David J. Posson

David J. Posson

Janet and Harry Pottinger

Jean L. Puleo

David S. Pumpelly

Teri M. Quick

John R. Raben, Jr.

Raising Hope for Others

Krystyn Rawlinson

Tui and Joseph M. "Joe" Reidy

Joy C. and William J. Schaefer, Jr.

Chase and Michael Scott

Karen R. and John W. Sechrist

Richard F. Sedlak

Anita Sellers

Garrett Smith

Hillary A. and Jackson R. Stephens

Terry and James K. Stoller, MD, MS (Org.Dev.)

Pamela and Sidney Suggs

Anne D. and Rhea M. Sumpter

Estelle Tenant Patricia L. Tew

The Barbara and Edward Netter Foundation

The Begley Family Foundation

The Doug and Tamra Adams Foundation

The Ergonomic Group

The Greater Kansas City Community Foundation-

Haverty Family Foundation Fund

The Jacob 219 Fund

The Mulligan Family Fund-David Mulligan and

Kim Arnowitt

The Olivieri Johnston Family Foundation

The Russell and Bornstein Family Charitable

Fund

The UK Online Giving Foundation

Catherine Vernon

Scott Walls

Kay and Robert Walter

Megan L. Watkins

Wave Life Sciences

Willie D. Wiggins

Kathleen A. Williamson

Andrew A. Wilson, MD

Anthony Wong

Worldcom Exchange, Inc. (WEI)- Mike Thweatt

Julie W. Wright

Linda and Robert Yoder

Claudia and D.C. Young

Your Cause, LLC

Martin R. Zamora, MD

\$500 - \$999

Anonymous Donors

Jonathan E. Ansley

David Baird

Susan Barnes

Anya-Nicole and John C. Barrett

Beam Therapeutics, Inc.

Julie L. Berry

Kari F. and David Black

Andrew Blair

Misty and Greg P. Blessley

Anne S. and Gary F. Brendel

Connor J. Britt

Lynda B. Broad

Rollin A. Bush

William D. Byrne, Jr.

Sarah Camp

Nancy M. Carlson

Susan and Scott D. Casmer

Courtney Collins

Tricia Cotten

Andy Croft

Clarissa and Ronald G. Davidson

Charles DeLacey

Mark B. Delvaux

Jennifer Duralia

Linda and John K. Fielder

Michael Gaeta

Givinga Foundation, Inc.

Mary A. and Robert L. Greene, Jr.

Pat F. and Charles B. Griffis, Jr.

Claude H. Guion, Sr.

Cathey F. Henderson

Maureen and Gene A. Hochberg

Angela M. and Eric D. Hoglund

Bonnie L. and David E. Hoglund

Thomas R. Holland

Cora M. and Kenneth D. Hoskins

Finn Hurley

IBM Employee Services Center

Innovative Installations, Inc.

Kenneth Irvine, Jr.

Gregory P. Judge

Christine Keen

Paul C. Kimball

Breonna Kusick

Phillip J. Langlois

Phillip R. Lauderdale

Siobhan C. and Ryan Lestina

Betty J. and Alan E. Liberty

Steven E. Lindahl

Deborah Locke

Loyceta A. and Curtis R. Maslen, MD

Patricia A. and Joseph E. Masterson

Kory M. and John Matheis

Angela T. McBride

Victoria McGrane and David Scannell

Becky and Jon Medved

Mary and Robert Mendenhall

Kristin Midthun

Suzan and Mike Miller

Corinne A. and Donald H. Mitchell

Linda and Dennis L. Nelson

Pamela S. Nicosin

Adam Nunes

Octapharma

S. Richard Penni

Sharon W. and Barnet Phillips

John R. Ponton, Jr.

Marla and James R. Reese

Linda C. Renwick

Bridget A. Reynolds

Marcia F. Ritchie

Robert E. Sandblom, MD

Dorothea "Dot" and Robert A. "Sandy" Sandhaus, MD, PhD

Scott Santarella

Robert W. Schroff, Jr.

Gary J. Seitz

S.H. Bell Co.

Sharon and Arthur L. Shoener

Daniel W. Smith

Geralyn S. and Randy Smith

Chris L. Snell

Emily J. Sprague

Tampa International Forest Products, LLC-Joseph

Brown

Lois and Christopher Teeter

The Cobb Family Foundation

The Schlang Fund-Robin C. Diamant

The Southcott Agency, Inc.- Michael W. Southcott

The Teagle Foundation- Gwen Robbins

Anne K. Thomas

Sylvia A. Thomson

Mr. and Mrs. Tom Tibbatts

Lawrence A. Twisdale

United Way of Chester County

United Way of the Greater Lehigh Valley, Inc.

USUWRB Surgery Wardroom

Debbie Waldrop, RN, MSN

Dr. Joan L. Walker

Janelle Wall

Pamela and Fred C. Walsh

Patricia Wampler

Doris and Adam Wanner, MD

Noel Weil

Mark D. Wewers, MD

Kathleen S. and Robert H. Whitby

Memory L. Whitlock

Susan Wilder

Eric Williams

Donna Womack

Peter Worley

Yecuris, Inc.

Wendy and William Zabel

Denotes Deceased

The Alpha-1 Foundation received donations in memory of the following individuals between July 1, 2021 and June 30, 2022.

Kevin J. Ahearn Ann M. Alciatore Alpha Angels

Judith L. "Judy" Anderson Kenneth J. "Bo" Anderson

Lars A. Anderson Melvin B. Anderson Robert Anderson Fred Ashmore

Claire M. Aspen-Sullivan

Michael W. Axsom Arlynn Baber Sandra E. Bain

Kenneth A. "Kenny" Bakaitis

Judith "Julie" Crowell Bakula Magnus Ball

Nancy H. Barnhart

Kathleen E. (Deegan) Barone Dorothy and Michael J. Barth

Dwayne A. Bates Merle J. Baumhover Jan R. Bausinger William M. Bell Colin Bender

Dwight D. "Ben" Bender

David R. Bennett

Edward B. "Eddie" Berman

Susan K. Binnall Ann Clement Black Hilliard M. "Mike" Blair Mary J. "Jane" Blair Karen E. Blunt Grant W. Boam

Richard A. "Rick" Bohn James L. "Jim" Boling Kenneth Bourgois Edward H. "Ed" Brailey

Mary B. Braswell Alice K. Brazil

James "Jim" Brenna Rosalie A. Brosz

Cindy M. Bruntz

Richard A. "Dick" Bueker

Robert C. Bueker Sally J. Bulton John O. Byrne Pilar Cabiya

Amelia Cabiya-Martinez Gordon E. Cadwgan, Sr. Robert C. "Bob" Campbell

John P. Cannan Kenneth S. Carothers Carolyn J. Carter Benjamin C. Cash Nina Castaneda Anthony Castellone Stanley J. Castle George E. Catanakis Donald J. Ceppi

Francis A. and Marion A. Ceppi

Sharon Ceroll

Gary "Chris" Christensen

Niels Christensen Charles Christy

Constance J. "Connie" Chura

Teresa Cimino
Tommy Clayburg
Terry L. Cleaveland
Benjamin J. Cochrane
Nancy J. Coleman
Albert "Curts" Cooke
James P. Cooke
Roger F. Cooper, III
Stephen E. Cooper
Dennis Cosgrave
Joe Cosgrave
Casey S. Coulson
Robert Covington
Fred G. Crabb

Victoria D. "Vicki" Cronk Noah D. Crouch

Evangeline J. Curtis Joseph Danley

Robert "Bob" Daughtridge

David R. Davis, Sr.
Donald E. Davis, Sr.
Eunice G. Davis
Steve Dawson
Rich P. Dean
Elaine M. Decker

Frank Deford

Lois S. DeSimone

Kenneth S. "Ken" DeSieghardt

Michael E. DeWald Florence Dexter Patricia Dix Colleen Dobbs Michael J. Doolittle Reginald Dorff Randy Ervin Dossat Robert J. "Bob" Doughty Thomas John Downie Michael R. Duffy

Laureen Dunton Kirk R. Dye Nita L. Dykes Mary Etter

Sarah E. "Sally" Everett, Esq. Jeremy E. "Cheetah" Fahey

Donald Fairey
Ralph Farrar
Martha J. Faust
Curtis Fendley
Nancy Ferguson
Frank E. Fern
Allan R. Fetters
Nancy B. Feuerbach

Ron Fields Joyce Finch

Francis "Frank" Finnegan Dennis "Denny" Fisher

Sarah Follett
Philip M. Foster
Vernon D. Fowler
David Frang
Karen L. Fraser
Ron Fraser
William Fraser

Andrew A. Fredericks Seymour Freedman, MD

Richard J. Fricke
Sharon S. Friedman
Roger Fruchey
Sam Fulkerson
Julie Gaither

Cheryl Galttana

Alexandra P. "Lexie" Gardner

Ray Gastgeb

Robin L. Gatzimos

Carl F. Gebhardt, Sr.

Linda M. Gelineau

Fred L. Geis

Cindy Jo Gill

James "Jim" Charles Goering

Minnie Goodlett

Helen C. "Cathy" Gould

E. Sherman Grable, III

Frank Granfors

Roger S. Greene, Sr.

Anne D. Greenwood

Jean M. "Jeanie" Griffith

Robert J. "Bobby" Grimaldi

Phyllis A. Grundtner

Richard "Dick" Guptill

Larry J. Haan

Mike Haas

Roy P. Hackman

Patrick L. Haggerty

Eliza Mozelle Halton

James C. Hamilton

Sharon K. Hampton-Blevins

Robert S. Haner

Eric Hansen

John D. Hanshaw

John F. Hanson

Robert A. Hantke, Jr.

JoAnn R. Harkins

B. Yvonne Harris

Sondra "Ruth" Harrity

James P. "Jim" Hawkins

Dorothy "Dottie" Hayes

Thomas C. Hazen

Nancy Hearte

Gregory Heath

John Heidema

Thomas M. Helms

Daniel "Dan" Henderson

Andrea "Andi" Henry

Pamela Herman

Julia Hernandez

James P. "Jimmy" Herrin

Rebecca Hicks

Richard Higby

Terrance "Terry" Highland

Steven C. Hildreth

Shaylynne S. Hill

Charles R. Hillegass

John C. Hirschi

James "Jim" Hixon

Timothy "Tim" Harry

Holdeman

Dianna L. Holt

Jesse K. Hook

Rhonda Moore Hook

Candace Hopkins

Diane "Katie" Hopp

Diane Ratie Hopp

Jeffrey Scott Horsak

Richard W. Horsak

Toni and Keny Hoskins

Kenneth and Scott Houchin

Gregory J. Hules

Jackie Hutzell

Susan A. Hyatt-Caiaccio

Catherine L. Illian

Bettina B. Irvine

Bettina B. II ville

Donald A. Iwen

Patricia L. Jackson

Carol B. Jankowski

Peggy Jensen

Kenneth L. Jespersen Mary J. Johnson

Donald Johnston

Victoria T. "Vicki" Joseph

David O. Joyce

Oliver James Joyce

Alan Kaplan

Russell Kaylor

Margaret "Peggy" Keith

Catherine M. Kelley

Arno D. Kester

Kenneth F. Kiernan

Brenda Kilner

David R. Kinnius

William S. Kirk

Cindy C. Kirkeby

Helen Kline

Jack L. Koenig

Jeffrey L. Koenig

Lorraine J. Kordis

Doris V. Kramer-Roberts

Edward N. Krapels

Linda V. Krumel

Helen and Robert Kukura

John E. Kushner

Nancy J. Kutzler Jane Lambert

Wanda S. Lambert

Jerome L. "Jerry" Lange

Margaret M. Langlois

Paul LaPorte, Jr.

Thomas E. Largura

Deborah A. Lashway

Elsa A. Lauten

Sandra L. Lawrence

Robert Lee

Gregory C. Leigh

Stephen B. Lender

Roberta A. Leslie

David E. Lewis

Margaret Lewis

ivial galet Levi

Sandra Lewis

LeRoy V. Lim

Timothy B. Lewis

Alexandra J. "Sandy" Lindsey,

Co-Founder

Lynda Clare Lindsey

Nicholas B. Linnenberger

Michael D. Livingood

Michael G. Locke

Wanda Logsdon

Lorna Lomack

Maria E. Loss

Lvnn M. Lothian

Ricky Dale Lough

Robert "Randy" Lyon

Daniel B. MacArthur

Patricia E. MacInnes

Robert C. Maffit

James P. Mara

Lynette Marcum

Stacy C. Marcum Greinwald

Shirley L. Marnett

Gayle Marriott

Thomas L. Martin

Tonya L. Mashek

Judi R. Matich

Gracie Mattocks Don McAmis

Cynthia A. "Cindy" McAndrews

Alyce Mae (Carlson) McArdle

Mark D. McAuliffe

Robert D. McAuliffe

Michael L. McCamy

Gary J. McCarthy

William "Billy" McClellan Ames McKinsey

Stanley M. McLeod

Kevin A. McMackin

Lawrence P. McNamara William McNamara Sara P. McVay Orval H. Meinecke Francis N. Meister Joanne M. Mellady Nancy Merchant Jennifer Meredith Edward "Ed" Mikell Richard K. "Dick" Mill Ernest H. Miller Tim Miller Leslie F. Millick Gaylynn Minnigerode Kenneth L. Minnigerode Michele D. Mitchell Dolline Mixter

Allan D. Moore
Jeremy Moore
Teresa M. Moreira
Deborah L. Mocas
Melissa B. Moeschl
Celeste B. Morris
Gerard T. "Jerry" Morris

Katherine H. "Katie" Moyer Jerry W. Mullen William Mulqueen John A. "Jack" Murphy Shirley Murphey

Darrell J. Nall Keith Nash

Heilwig A. Nations
Jamy R. Nelson
Dean Nettleton
Lila Nevergold
Datricia E. Dunn Never

Patricia E. Dunn Nevers

Carol D. Noggle Roxanna Nowak Annette C. Obermier Debra S. "Debbie" Odell

Bruce T. Ogg Carole O'Mara

William D. "Billie" O'Quinn

Bonnie S. Pace Graham A. Page, DDS

Clayton R. Palmer

Jerome A. "Jerry" Palmer

Paula L. Parker Sally Parks

Billy R. "Bill" Parrett

Julianna Patterson William G. Payne Glen A. Perkins David M. Perreault Thomas "Tom" Peters Eric J. Peterson

Calvin T. "Cal" Piearcy

Evelyn Piearcy

Ronald E. "Ron" Piearcy

Richard Alan Pine Mark E. Pittinger Dennis W. Pollock Charles Poore Sandy Peggy Porter

John Potash
Robert L. Potash
Cynthia M. Potter
David M. Powley
David R. Purdam
Gregory E. Purdy
Barbara J. Pusey
James A. "Jim" Quill
Kathleen M. Quinlan
Robert A. "Bob" Rackers

Michael Ratner Albert W. "Ab" Rees Cecil Ray Redmill William F. Reese Steven W. Rehm Vivian B. Riley Marilyn "Lyn" Roberts

Shea Robertson Mary Beth Roof Jackson N. Root Mike Rosella

Martha A. Roundtree Edward Roxberry Ora J. Royal, Jr. Jeanne E. Ruff James D. Ruhland Robert C. Ryan John Owen Sams Robert Joseph Savard Kathleen M. Schaefer

William J. "Bill" Scheuerman Rose and Jack Schiller Lawrence Schmidt

Martha L. "Marti" Schnellback Kimberly J. Scholle

Lynn Schowalter

Nancy Jean Schrum Patricia A. Schutter Allen Schwark Jim Schwarz Stephen W. Sealy

Randall W. "Randy" Sedlak

Helen Segar Susan L. Seitz

Aldona J. "Mimi" Sekarski

Keith Sellers

Tamara M. "Tammy" Short

Donna L. Shroyer Daniel S. Shryack Wayne A. Simoneau Mike Skivington Karen J. Smack

Elizabeth "Beth" Smith

Lorna Smith

Margaret M. "Peggy" Smith

Norma L. Smith Ronlyn S. Smith Vicky Smith

Martha L. Snellback Gordon L. Snider, MD

Davis Snyder James T. Snyder

Gerald A. "Jerry" Soderquist

Donna Sommatino Shelly K. Sparks Jane Bond Sperling Deborah L. Sprunger Susan Gerrard Stanley, Co-

Founder

Mary Ann Stanton John D. Starling

Andrew C. "Andy" Steele

Pamela C. Steele

Anthony A. "Tony" Steier

Sue Steinmetz

Francis J. "Frank" Stevenson LaVonne "Scottie" Stewart

Dr. Dennis H. Stiles Robert P. Stoker Marta C. Strock

Randall "Randy" Strock

Ellen L. Sullivan Victor J. Sullivan, Jr. Rhea M. Sumpter, MD Douglas J. Sundlie Robert W. Taylor

Richard L. Teunissen

Peter M. Thomson

Suzanne Tierney

Gayle A. Tipper

Gerald "Jerry" Treichel

Kevin M. Treu

Louis "Buzz" Trevathan

James A. "Jim" Trimble

Steven Trost

Lon E. Tryggestad

Roslyn Upoff

Cathy Urish

Ivana Vandenberg

Kenneth Ver Haagh

Ken Vickers

Barbara Visser

Ed Von Kattengell

Manolo Vuelta

Denis Vuelta-Alvarez

Lela S. Wagnon

Joel C. Walcott

Helen Chase and Jack "Coach" Walsh

John W. Walsh, Co-Founder

Nancy Watson

Howard Werdehoff

Betty Westbrook

Virginia L. "Ginny" White

Loyce B. Whitlock

Ralph "Steve" Whitlock

Wilbur A. Whitlock

Karen Wiggins

Doug Wiles

Joan Willert

Patricia G. Williams

Raymond S. Wilson

Thomas B. "Buzz" Witt

Gerald C. Wolcott

Scott S. Worlton

Jackie L. Wriston

Willogene Wriston

Terry L. Young

Dr. Wayne S. Young

William E. Young

Joseph G. "Joe" Yout

In Honor Of

The Alpha-1 Foundation received donations in honor of the following individuals between July 1, 2021 and June 30, 2022.

All Alphas

Shirley J. Allen

Alpha-1 Foundation Staff

Alpha-1 Research Doctors

AlphaNet Coordinators

Alphas for Building Friends for a Cure

Ann Amoroso

Karen K. Anderson

Dwayne A. Bates

The Beck Siblings

Wendy Becker Peyton

Thomas K. Bell

Daniel J. Beltrani

Kenneth E. Benson

Kari F. Black

John S. Bradley

Mark L. Brantly, MD

Thomas A. Brown. Jr.

Jennifer and Tony Browne

James D. Buckley

Ruth and Gordon E. Cadwgan, Jr., PhD

Caregivers of Alpha Patients

Judith A. Carline

Kiara Casmer

Bianca, Chase & Ava Castillo

Marcia M. Chapter

McKinley Chittick

Lorraine Cimino

Ella and Nathan Cohen

Karl F. Cook

Albert "Curts" Cooke

Elaine A. Croucher

Jeanine D'Armiento, MD

Darlene A. Dartt, PhD

Barbara E. and Donald A. Davis, Jr.

Andrew DiDomenico

Delores A. Dissinger

Steve R. Donovan

Caden Dorfman

Karen L. Erickson

Justin Everett

Eileen L. Fern

Susan and Donald C. Ferro

Ben and Jill Fleming

Louis G. Fox

Gregory Frank

Paul Friedlander

Katherine A. Gallop

Kurt Gamlin

Brady Garcia

Catriona L. Garry

Ted Geiger

Monica P. Goldklang, MD

Joanne and Joseph Gonzalez

Ginny Green

Robert L. Greene, Jr.

Daniel F. Grimm

Patricia Hager

Jon E. Hagstrom

Melissa M. Hall

Jennifer and Matt Harader

Rebecca and Gary Harmon

Nichelle N. "Nikki" Hayes

Linda L. Hazelbeck

Jeffery L. Hildebrandt

Marion and Larry Hoffman

Gary Hoffmeyer

The Hoglund Family

Debbi Howells

Mary Hughes

Kenneth A. Irvine

Abby Jameson

Jeffrey E. Jewell

Christine Johnson

Danielle M. Johnson

Lois L. Johnson

Grace and Lucas Johnson

James M. Keith

Peter S. Kelley

Debby Kelly

Lisa A. Kosak

Dorothea L. "Dee" Kroecker

August Eskered Kroll

Victor L. Kroll

Constance "Connie" Lilly

Elizabeth "Ellie" Lindloff

In Honor Of

Kaitlyn "Katie" Lindloff

Larry Lindsey

Starr B. Locke

Dr. Harry Long

Brian Lowery

Julie MacNiel

Ricky A. Maddox

Jonathan "Money Maker" Maidment

Karen and David Maidment

Gillian L. Marcott and William Irvine

Ren, Harmony and Melody Marcum

Melissa Marko

Donna Marley

Robert E. "Bob" Martens

The Maslen Family

Patricia "Patsy" and Joseph E. Masterson

Wendy and Keith McKenna and Sons

Jim McVey

Bruce A. Miles

Nancy L. Moga

Isla R. Monti

Griffin P. Morris

Julie Murray

Elizabeth Myers

Bryan D. Nelson

Martha Nevergold

Patricia Nevergold Robert B. Nichols

Terry R. Nickerson

Miriam A. O'Day

Cl. LLD L

Sharon H. Pacelli

Scott Parks

Kenneth Pease

Debbie Peltzer

William Perry

Emilie M. Redpath

Joseph M. "Joe" Reidy

Patrick J. Reynolds

Sam Reynolds

Clarissa D. Riely

Ethan Roehrich

Dorothea "Dot" and Robert A. "Sandy" Sandhaus, MD, PhD

Ana Santos

Cameron Sapp

Bardie Scarbrough

Joy C. Schaefer

Jacob Schut

Carol Ann Shipp

Steven J. Snyder

Lynn Soriano

William T. Spilker

Cynthia and Donald J. Stagg

Harrison Clay Stephens

Ronald A. Stephens

James M. Stocks, MD

Charlie Strange MD

Sam Talarico

Lawrence Tandol

John W. Thiesen

Kenneth J. Thime

Michael G. Thomas

Jonas Tretter

Beckett James W. Van Dijk-Smith

Carolyn P. Vanderberg

Kitty Vieth

Diane L. Walsh

Juba Walsh

Pamela and Fred C. Walsh

Warren E. Waterman

Virginia E. "Ginger" Watkins

John C. "Jay" Whitmore, Jr.

Robert N. Williams

James K. Wilson, III

Casey Wolff

Joshua C. Wolff

Matthew Wolff

Michael Wolff

Marian M. Yasuda

Claudia and DC Young

Caroline L. Zeigler

Denotes Deceased



Our Mission

The Alpha-1 Foundation is committed to finding a cure for Alpha-1 Antitrypsin Deficiency (Alpha-1) and to improving the lives of people affected by Alpha-1 worldwide.

The Alpha-1 Foundation has invested over \$91 million to support Alpha-1 research and programs at 123 institutions in North America, Europe, the Middle East, and Australia.

www.alpha1.org 1 (877) 2 CURE A1 | 1 (877) 228-7321